Please assess the completion status of the following clinical trial:

Trial Title: Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Incl. Criteria Patients with clinical diagnosis of stable Chronic Obstructive Pulmonary Disease (COPD) according to definition of China COPD guideline.~Patients over 40 years old~Exclusion Criteria:~Patient with history of hypersensitivity to tiotropium bromide, atropine and/or its derivant, i.e. ipratropium, or any component of Spiriva® Patient with known narrow-angle glaucoma~* Patient with known symptomatic prostatic hyperplasia and/or bladder-neck obstruction~* Patient with known moderate to severe renal impairment (i.e.,creatinin clearance\<=50ml/min)~* Pregnant or nursing women~* Patient with any significant disease other than COPD which would exclude him/her from participating in the study~* Patients with any conditions listed in \[special precautions\], \[drug interactions\], and \[contraindication\] of Spiriva® China package insert~* Patients with signed informed consent of any other study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).